NCT07187908

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,076 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN

Conditions

• Primary/Secondary Prevention
• High Risk for Febrile Neutropenia of Chemotherapy Regimens
• Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia

Interventions

Type	Name	Description
DRUG	Efbemalenograstim alfa Injection	The patients with solid tumor who were at high risk for febrile neutropenia or intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia would be injected Efbemalenograstim alfa for primary/secondary prevention.

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-10-01
• Completion: 2027-10-01
• First posted: 2025-09-23
• Last updated: 2025-09-23

Locations

1 site across 1 country: China